Analysis often reveals variability in the composition of ecstasy pills from pure 3,4-methylenedioxymethamphetamine (MDMA) to mixtures of MDMA derivatives, amphetamine, and other unidentifi ed substances. For a comprehensive toxicological analysis one needs to know all steps to MDMA synthesis which may originate impurities. The aim of this study was to synthesise and determine the chemical-physical and in vitro biological properties of a series of MDMA derivatives. 3,4-methylendioxyphenyl-2-nitropropene (MDNP) was obtained by condensation of piperonal with an excess of nitroethane in the presence of ammonium acetate. MDNP was then reduced to methylenedioxyamphetamine (MDA) by LiAlH 3 . All compounds were analysed using HPLC and spectroscopic technique [Raman, nuclear magnetic resonance (NMR), or infrared (IR)] at all the steps of synthesis. In addition, we assessed the biological potentials of these compounds by measuring in vitro their (i) blood cell/whole blood partition coeffi cient, (ii) binding to plasmatic proteins (Fbp), and (iii) membrane adsorption. Chemical structure was determined with antibody fl uorescence polarisation immunoassay (FPIA). This study showed the presence of solid impurities, particularly of a neurotoxic compound of Al 3+ in the fi nal products. FPIA identifi ed the aminoethane group close to the substituted benzene ring, but did not detect the two major precursors of MDMA: MDNP and piperonal. Raman spectroscopy is an attractive alternative technique to characterise ecstasy pills and it can identify stereoisomeric forms such as cis-MDNP and trans-MDNP, which exhibit signals at 1650 cm -1 and 1300 cm -1 , respectively.
Ecstasy is a synthetic drug used recreationally worldwide, especially by young people, which makes it a major public health concern (1) . A recent French study with 1666 ecstasy pills carried out by a non-governmental organisation Rave Mission revealed that the pill composition varied from pure 3,4-methylenedioxymethamphetamine (MDMA) to a mixture of ecstasy derivatives, amphetamine, and 20 % of other substances unidentifi ed by Rapid Product Control (RCP) (2) . There are several possible ways to synthesise ecstasy, all of them starting with piperonal to obtain either a ketone (3,4-methylenedioxyphylpropanone) or an amine chemical form (3,4-methylenedioxyamphetamine) (2) . Various impurities and by-products were identifi ed in powdered tablets: 3,4-methylenedioxyamphetamine (MDA), MDA or MDMA dimers, substituted pyridines, lead, aluminium, and nitroethane (3, 4) . Some of these compounds are toxic and could be involved in documented cases of fulminant toxic hepatitis and neurotoxic effects (4) .
This suggests that a comprehensive toxicological analysis of an ecstasy pill requires expert knowledge of all synthetic steps and identifi cation of impurities. Raman spectroscopy is a powerful technique to characterise ecstasy pills. In addition, it is an in situ, non-destructive technique that identifi es chemical bonds through intramolecular vibration spectrum (5-7). The technique has proven successful in several published studies of illegal drugs (8, 9) . In addition, Raman spectroscopy was used to probe photoexcitated phase transition with second irradiation using nanosecond pulsed laser leading for example to colour changes (10) . These properties could be exploited to identify organic metals in a sample.
The aim of our study was to fi rst synthesise a series of MDMA derivatives, then to characterise them using HPLC and spectroscopic techniques [Raman, nuclear magnetic resonance (NMR), or infrared (IR)], and fi nally to establish their biological effects on blood cells, proteins, anisotropic polar membrane, and antibodies. To obtain 3,4-methylendioxyphenyl-2-nitropropane, we added NaBH 4 (0.02 mol) to a solution of MDNP (0.01 mol) in methanol (25 mL) by stirring at 5 °C to 10 °C. After allowing the reaction to continue for another hour at room temperature, the mixture was concentrated. Excess of NaBH 4 was decomposed with acetic acid and extracted with chloroform.
MATERIALS AND METHODS

Chemicals
CHARACTERISATION
HPLC
The precursor and fi nal products were determined by HPLC equipped with a UV detector. The mobile phase consisted of methanol:H 2 O:trifl uoroacetic acid (60:40:0.01). Eluation was in isocrat mode at the fl ow rate of 1 mL min -1 . HPLC separation was performed on a reverse-phase C 18 column (LiChrospher 60, RP-select B ,125 mm x 4 mm, with 5 µm sized particles). 
NMR spectroscopy
Raman spectroscopy
Spectra were acquired using a Dilor XY1800 triplemate spectrograph coupled to a Princeton Instruments CCD detector. The 647.1 nm line of a Kr + laser (Coherent Radiation Innova) was used as the excitation source with laser power of 50 mW. Raman signals were collected at room temperature, at 180 °C to the incident laser beam in the 170 cm -1 to 2400 cm -1 frequency range. Rayleigh scattering was removed using a holographic notch fi lter.
Infrared spectroscopy
IR spectra were recorded on KBr discs with a Perkin-Elmer 983 spectrometer. For all the studied compounds we scanned four accumulations between 400 cm -1 and 4000 cm -1 with 2 cm -1 resolution.
Biological characterisation
The biological potentials of compounds were assessed from in vitro measurements of their fraction bound to plasma proteins coeffi cient (F bp ), determination of blood cell/whole blood partition coeffi cient (F cb ), membrane adsorption coeffi cient (F ad ), and interaction with specific anti-MDMA antibody. These biological methods were described elsewhere (12) .
Determination of F bp
200 µL of plasma spiked with the studied compound (0.1 nmol L -1 ) was incubated in a water bath at 37 °C for 15 min and placed in an ultrafi ltration cell. After centrifugation in an SM24 centrifuge (Dupont Instruments; Wilmington, DE, USA) at 1978 g for 20 min, the ultrafi ltrate was analysed using HPLC. The unbound to protein fraction (F up ) was determined by calculating the ratio of the concentration in ultrafi ltrate and the initial compound concentration in plasma. The fraction bound to plasma proteins was deducted from the following equation: F bp =100 % -F up .
Determination of F cb
20 µL of physiological solution of each compound at concentration of 1 mmol L -1 was added to 2 mL fresh blood taken on EDTA tripotassium salt (K 3 EDTA). After incubation for 15 min at 37 °C, the blood sample was centrifuged (at 2000 g for 15 min) and 200 µL plasma were taken to determine the concentration in the ultrafi ltrate (see determining F bp above). Calculations were performed using the following equation:
The free fraction, which is neither bound to blood cells nor to proteins, was determined using the following equation:
where F cb is the blood cell/whole blood partition coefficient; C bt the concentration in total blood (0.01 mmol L -1 ); C uf the concentration in ultrafi ltrate; F up the unbound-to-protein fraction coeffi cient; h is haematocrit; F bp binding to plasma proteins coeffi cient, and F fr the free fraction coeffi cient.
Determination of F ad
200 µL of physiological solution of each compound (1 µmol L -1 ) were centrifuged through permeable anisotropic membrane (Amicon) at 1978 g for 20 min (SM24 centrifuge, Dupont Instruments; Wilmington, DE, USA) and the ultrafi ltrate was analysed using HPLC. The coeffi cient of membrane adsorption was estimated using the following equation:
where F ad is the membrane adsorption coeffi cient; C is the concentration in initial physiological solution; and C su the concentration in the ultrafi ltrate.
Interaction with specifi c anti-MDMA antibody
Physiological solution of each compound (0.01 mmol L -1 ) was analysed using an automated FPIA system (Abbott AxSYM ® , USA).
RESULTS AND DISCUSSION
In this study, we have described the synthesis route starting from piperonal and ending with 3,4-methylenedioxyamphetamine (MDA) (11) . We have also reported the synthesis of 3,4 methylendioxyphenyl-2-nitropropane, which is not considered precursor of MDMA. We used 3,4 methylendioxyphenyl-2-nitropropane to study its interaction with specifi c anti-MDMA antibody.
MDNP and MDA were obtained with high chemical purity. The synthesis reactions were followed by HPLC determination of retention times of the obtained products. Piperonal, MDA and MDNP exhibited high lipophilicity (Figure 1 ). The retention pointing to amines, and by the disappearance of the nitro signals. Figure 2 shows the vibrational modes of piperonal, MDNP, and MDA plotted in the range of 250 cm -1 to 1750 cm -1 . While piperonal and MDNP showed high quality Raman spectra (Figure 3 ), MDA showed a spectrum with a rather large background, possibly due to a fl uorescence in the system at either 632 nm or 541 nm (Figure 4) . Milhazes et al. (9) obtained MDA spectrum at 541 nm. Table 1 lists the biological characteristics of the ecstasy derivatives and impurities in the fi nal product. Of solid impurities found, a neurotoxic compound of Al 3+ is of particular interest (4). Save for F bp , all other biological parameters seem to be proportional to their retention time determined by HPLC and to their lipophilicity. Retention times for piperonal was 2 min, for MDA and 2.5 min, and for MDNP 3.1 min and corresponded to F ad and F bp . Table 1 shows that the percent of free compounds in plasma is less than 40 % of total blood concentration: F fr =23 % for piperonal, F fr =27 % for MDA, and F fr =38 % for MDNP.
FPIA antibody recognised the aminoethane group close to the substituted benzene ring, but did not detect the two major precursors of MDMA, that is, MDNP and piperonal ( Figure 5 ). This limitation must be taken into consideration, as detection of all ecstasy 
CONCLUSION
This study has detected solid impurities and by-products in the synthesised products: MDA, unreacted piperonal, MDNP, and aluminium. While HPLC, Raman, and IR spectroscopy identifi ed ecstasy derivatives, FPIA did not detect MDNP and piperonal. Raman spectroscopy has turned out to be a particularly interesting alternative technique for characterising ecstasy pills, as it can determine stereoisomeric forms of compound such as cis-MDNP and trans-MDNP at 1650 cm -1 and 1300 cm -1 , respectively. Our findings call for further study of Raman spectroscopy to better characterise other drug derivatives.
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